Is it time to rethink the Alzheimer's disease drug development strategy by targeting its silent phase?
Neural Regen Res
; 13(2): 224-225, 2018 Feb.
Article
en En
| MEDLINE
| ID: mdl-29557364
Texto completo:
1
Banco de datos:
MEDLINE
Idioma:
En
Año:
2018
Tipo del documento:
Article